Standout Papers
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial (2010)
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (2020)
Citation Impact
7 by Nobel laureates 4 from Science/Nature 68 standout
Citing Papers
The hallmarks of cancer immune evasion
2024 Standout
Renal cell carcinoma
2024 Standout
Works of Chen Mei being referenced
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
2020 Standout
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
2019
Author Peers
| Author | Hematology | Molecular Biology | PRM | Oncology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Chen Mei | 254 | 1556 | 2107 | 1160 | 59 | 2.9k | |
| Bradley D. Farmer | 3 | 87 | 4 | 38 | 632 | ||
| Alexander Gribov | 10 | 68 | 36 | 25 | 11 | 708 | |
| Annabel S. C. Thorn | 2 | 10 | 859 | ||||
| Walter J. Moretto | 17 | 182 | 5 | 70 | 14 | 1.4k | |
| Malika Oubaha | 17 | 394 | 32 | 67 | 11 | 743 |
All Works
Login with ORCID to disown or claim papers
Loading papers...